BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hernexeos (Zongertinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hernexeos (Zongertinib)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06151574-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT06151574)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) 
 Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations 
 Compared With Standard Treatment\nEstimated primary completion: 10 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06151
 574
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789028-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Hernexeos (Zongertinib): Phase 1 readout est. (NCT07789028)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 1.\nStudy: A Study in Healthy P
 eople to Test How Zongertinib is Taken up in the Body When Given as Tablet
 s Made by Two Different Manufacturers With or Without Food\nEstimated prim
 ary completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zongertinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07789028
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Hernexeos (Zongertinib): Phase 2 readout est. (NCT07486817)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion 44: A Study to Test How Well Zongertinib is Tolerated by 
 People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When G
 iven in Combination With Chemotherapy With or Without Pembrolizumab\nEstim
 ated primary completion: 12 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zongertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04886804-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Hernexeos (Zongertinib): Phase 1 readout est. (NCT04886804)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 1\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in
  People With Different Types of Advanced Cancer (Solid Tumours With Change
 s in the HER2 Gene)\nEstimated primary completion: 29 February 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04886804
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619066-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Hernexeos (Zongertinib): Phase 2 readout est. (NCT07619066)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 2.\nStudy: A Phase II Study of 
 Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negativ
 e Advanced Breast Cancer Harboring HER2 Mutations.\nEstimated primary comp
 letion: 28 September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zongertinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07619066
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581432-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Hernexeos (Zongertinib): Phase 2 readout est. (NCT06581432)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 2.\nStudy: Beamion PANTUMOR-1: 
 A Study to Test Whether Zongertinib Helps People With Advanced Cancers Wit
 h HER2 Alterations\nEstimated primary completion: 30 November 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06581432
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899801-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Hernexeos (Zongertinib): Phase 1 readout est. (NCT07899801)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 1\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In H
 ER2-Mutated Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completi
 on: 7 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zongertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07899801
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928479-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Hernexeos (Zongertinib): Phase 1 readout est. (NCT07928479)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 1.\nStudy: Neoadjuvant Trastuzu
 mab\, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Bre
 ast Cancer: the TRAIN-5 Study\nEstimated primary completion: January 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07928479
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Hernexeos (Zongertinib): Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 1/2.\nStudy: Beamion BCGC-1: A 
 Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination
  With Other Treatments to Test Whether it Helps People With Different Type
 s of HER2+ Cancer That Has Spread\nEstimated primary completion: 8 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063243
 57
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195695-2274@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20320226
DTEND;VALUE=DATE:20320227
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT07195695)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in Peo
 ple With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2
  TKD Mutations\nEstimated primary completion: 26 February 2032. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07195695
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
